BeiGene, Ltd.
Anti-PD1 antibodies and their use as therapeutics and diagnostics

Last updated:

Abstract:

Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.

Status:
Grant
Type:

Utility

Filling date:

14 May 2018

Issue date:

31 Dec 2019